

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
27 April 2023 (27.04.2023)



(10) International Publication Number
WO 2023/067517 A1

(51) International Patent Classification:

C07D 487/00 (2006.01) A61P 43/00 (2006.01)
A61P 31/20 (2006.01) C07D 403/08 (2006.01)

(21) International Application Number:

PCT/IB2022/060055

(22) International Filing Date:

19 October 2022 (19.10.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/257,723 20 October 2021 (20.10.2021) US

(71) Applicant: **ASSEMBLY BIOSCIENCES, INC.**

[US/US]; 331 Oyster Point Blvd 4th Floor, South San Francisco, California 94080 (US).

(72) Inventors: **ZONG, Zhixin**; c/o Assembly Biosciences,

Inc., 331 Oyster Point Blvd, 4th Floor, South San Francisco, California 94080 (US). **WU, Yi**; c/o Assembly Biosciences,


Inc., 331 Oyster Point Blvd, 4th Floor, South San Francisco, California 94080 (US). **MOHAMMED, Noorullah, Naqvi**; c/o Assembly Biosciences, Inc., 331 Oyster Point Blvd, 4th Floor, South San Francisco, California 94080 (US). **WHITE, Nicole**; c/o Assembly Biosciences, Inc., 331 Oyster Point Blvd, 4th Floor, South San Francisco, California 94080 (US). **JOHNSON, Mark**; c/o Assembly Biosciences, Inc., 331 Oyster Point Blvd, 4th Floor, South San Francisco, California 94080 (US). **WALLACE, Michael**; c/o Assembly Biosciences, Inc., 331 Oyster Point Blvd, 4th Floor, South San Francisco, California 94080 (US).

(81) Designated States (unless otherwise indicated, for every

kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS,

(54) Title: NOVEL CRYSTALLINE FORMS

FIG. 1



(57) Abstract: The present disclosure generally relates to novel crystalline forms of a certain compound which are useful as modulators of hepatitis B virus core protein assembly. The present disclosure also relates to identifying suitable solid forms with promising solid state properties for clinical development. The solid state forms disclosed may be used in the manufacture of drug products which may have allosteric effector properties against hepatitis B virus (HBV) core protein (Cp), a protein found as a dimer, a multimer, and as the protein shell of the HBV core. As one example, provided herein is a stable crystalline form which may be useful for treating viral infections, such as hepatitis B.

[Continued on next page]

RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *of inventorship (Rule 4.17(iv))*

Published:

— *with international search report (Art. 21(3))*